References

arthyper

Артериальная гипертензия

"Arterial’naya Gipertenziya" ("Arterial Hypertension")

1607-419X2411-8524

Antihypertensive League

10.18705/1607-419X-2011-17-5-415-424

arthyper-1647

Research Article

ЛЕКЦИЯ

LECTURE

Гиполипидемическая терапия у пожилых пациентов. В фокусе — статины и прогноз

Lipid-lowering therapy in elderly patients: Focus on statins and outcome

Барсуков

А. В.

Barsukov

A. V.

avbarsukov@yandex.ru

Таланцева

М. С.

Talantseva

M. S.

noemail@neicon.ru

Свёклина

Т. С.

Sveklina

T. S.

noemail@neicon.ru

Багаева

З. В.

Bagaeva

Z. V.

noemail@neicon.ru

Зобнина

М. П.

Zobnina

M. P.

noemail@neicon.ru

Военно-медицинская академия им. С.М. КироваРоссияMilitary Medical Academy named after S.M. KirovRussian Federation

2011

28102011

175415424

2011

Барсуков А.В., Таланцева М.С., Свёклина Т.С., Багаева З.В., Зобнина М.П.

Barsukov A.V., Talantseva M.S., Sveklina T.S., Bagaeva Z.V., Zobnina M.P.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://htn.almazovcentre.ru/jour/article/view/1647

Пожилой возраст и дислипидемия — безусловные факторы высокого риска сердечно-сосудистой заболеваемости и смертности. В статье приведены доказательства пользы применения статинов в интересах первичной и вторичной профилактики сердечно-сосудистых осложнений у лиц максимально старших возрастных групп. Показана важность достижения целевых уровней липидов независимо от возрастной принадлежности. Отражены возможности комбинированной липидснижающей терапии. Освещены вопросы безопасности применения статинов у лиц пожилого и старческого возраста.

Elderly age and dyslipidemia are known high risk factors for cardiovascular morbidity and mortality. The article focuses on the evidence of statin benefits in primary and secondary prevention of cardiovascular complications in very elderly subjects. Importance of the achievement of target lipid levels regardless the age and possibilities of combined lipidlowering therapy in elderly patients are demonstrated. Some aspects of statin safety in elderly subjects are highlighted in the paper.

дислипидемияпожилой возрастстатиныкомбинированная липидснижающая терапия

dyslipidemiaelderly agestatinscombined lipid-lowering therapy

References1

American Heart Association. Older Americans and cardiovascular diseases statistics. 2004. Available at: http://www.americanheart.org/down-loadi-theart/11365844954980lderAm06.pdf. Accessed August 2008.

Aronow W.S., Frishman W.H. Management of hyperholesterinemia in older persons for the prevention of cardiovascular disease // Cardiol. Rev. — 2010. — Vol. 13, № 3. — Р. 132-140.

Wong N.D., Wilson P.W., Kannel W.B. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study // Ann. Intern. Med. — 1991. — Vol. 115, № 9. — P. 687-693.

Aronow W.S., Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease // Am. J. Cardiol. — 1996. — Vol. 77, № 10. — P. 864-866.

Castelli W.P., Wilson P.W., Levy D. et al. Cardiovascular risk factors in the elderly // Am. J. Cardiol. — 1989. — Vol. 63, № 16. — P. 12H-19H.

Lavie C.J., Milani R.V. National Cholesterol Education Program's recommen-dations, and implications of «missing» high-density lipoprotein cholesterol in cardiac rehabilitation programs // Am. J. Cardiol. — 1991. — Vol. 68, № 10. — P. 1087.

Corti M.C., Guralnik J.M., Salive M.E. et al. HDL cholesterol predicts coronary heart disease mortality in older persons // J. Am. Med. Assoc. — 1995. — Vol. 274, № 7. — P. 539-544.

Corti M.C., Guralnik J.M., Salive M.E. et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons // Ann. Intern. Med. — 1997. — Vol. 126, № 10. — P. 753-760.

Reuben D.B., Ix J.H., Greendale G.A. et al. The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur studies of successful aging // J. Am. Geriatr. Soc. — 1999. — Vol. 47, № 4. — P. 402-406.

Ettinger W.H., Sun W.H., Brinkley N. et al. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys // J. Gerontol. — 1995. — Vol. 50A. — P. M137-MI40.

Wolf P.A. Cerebrovascular disease in the elderly / In: Tresch D.D., Aronow W.S., eds. // Cardiovascular disease in the elderly patient. — NY: Marcel Dekker, Inc, 1994. — P. 125-147.

Aronow W.S., Ahn C. Correlation of serum lipids with the presence or absence of atherothrombotic brain infarction and peripheral arterial disease in 1834 men and women aged 62 years // Am. J. Cardiol. — 1994. — Vol. 73, № 13. — P. 995-997.

Suryadevara V., Storey S.G., Aronow W.S. et al. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease // J. Gerontol. Med. Sci. — 2003. — Vol. 58A, № 9. — P. 859-861.

Wannamethee S.G., Shaper G., Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men // Stroke. — 2000. — Vol. 31, № 8. — P. 1882-1888.

Bassuk S.S., Wypij D., Berkman L.F. Cognitive impairment and mortality in the community-dwelling elderly // Am. J. Epidemiol. — 2000. — Vol. 151, № 7. — Р. 676-688.

Zimetbaum P., Frishman W.H., Ooi W.L. et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: the Bronx Aging Study // Arterioscler. Thromb. — 1992. — Vol. 12, № 4. — P. 416-423.

Barsukov A., Bagaeva Z., Rezvantsev M., Shoustov S. Some metabolic patterns in essential hypertensive patients with different types of left ventricular hypertrophy // J. Hypertens. — 2009. — Vol. 2, Suppl. 4. — P. 90-91.

Барсуков А.В., Свеклина Т.С., Шустов С.Б. и др. Лабораторные маркеры кардиоваскулярного прогноза у пациентов с артериальной гипертензией в сочетании с сахарным диабетом и фибрилляцией предсердий // Вестн. Чуваш. гос. педагогич. ун-та. — 2010. — № 4. — С. 12-17. ЛЕКЦИ,

Соколова Л.А., Красильникова Е.И., Костромина Н.А. Метаболические изменения при гипертонической болезни // Артериальн. гипертенз. — 1997. — Т. 3, № 1, прил. — С. 54-55.

Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции // Артериальн. гипертенз. — 2004. — Т. 10, № 3. — С. 137-142.

Ades P.A., Poehlman E.T. The effect of exercise training on serum lipids in the elderly // Am. J. Geriatr. Cardiol. — 1996. — Vol. 5, № 5. — P. 27-34.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. — 1994. — Vol. 344, № 8934. — P. 1383-1389.

Pedersen T.R., Wilhelmsen L., Faergeman O. et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) // Am. J. Cardiol. — 2000. — Vol. 86, № 3. — P. 257-262.

Lewis S.J., Sacks F.M., Mitchell J.S. et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction // J. Am. Coll. Cardiol. — 1998. — Vol. 32, № 1. — P. 140-146.

Plehn J.F., Davis B.R., Sacks F.M. et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study // Circulation. — 1999. — Vol. 99, № 2. — P. 216-223.

The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up // Lancet. — 2002. — Vol. 359, № 9315. — P. 1379-1387.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial // Lancet. — 2002. — Vol. 360, № 9326. — P. 7-22.

Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial // Lancet. — 2002. — Vol. 360, № 9346. — P. 1623-1630.

Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // J. Am. Med. Assoc. — 2001. — Vol. 285, № 13. — P. 1711-1718.

de Lemos J.A., Blazing M.A., Wiviott S.D. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z trial // J. Am. Med. Assoc. — 2004. — Vol. 292, № 11. — P. 1307-1316.

Cholesterol treatment trialists' (CTT) eollaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins // Lancet. — 2005. — Vol. 366, № 9493. — P. 1267-1278.

Deedwania P., Stone P.H., Merz C.N. et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) // Circulation. — 2007. — Vol. 115, № 6. — P. 700-707.

Chaturvedi S., Zivin J., Breazna A. et al; for the SPARCL investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack // Neurology. — 2009. — Vol. 72, № 8. — P. 688-694.

Goldstein L.B., Amarenco P., Szarek M. et al. on behalf of the SPARCL investigators. Hemorrhagic stroke in the Stroke prevention by aggressive reduction in cholesterol levels study // Neurology. — 2008. — Vol. 70, № 24, Pt. 2. — P. 2364-2370.

Sacco R.L., Chong J.Y., Prabhakaran S., Elkind M.S. Experimental treatments for acute ischemic stroke // Lancet. — 2007. — Vol. 369, № 9558. — P. 331-341.

Szczepanska-Szerej A., Kurzepa J., Wojczal J., Stelmasiak Z. Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke // Pharmacol. Rep. — 2007. — Vol. 59, № 1. — Р. 94-97.

Ridker P.M., Danielson E., Francisco M.I. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein // N. Engl. J. Med. — 2008. — Vol. 359, № 21. — P. 2195-2207.

Aronow W.S., Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dL treated with statins versus no lipid-lowering drug // Am. J. Cardiol. — 2002. — Vol. 89, № 1. — Р. 67-69.

Aronow W.S., Ahn C., Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dL treated with statins versus no lipid-lowering drug // J. Gerontol. Med. Sci. — 2002. — Vol. 57A, № 5. — P. M333-M335.

Aronow W.S., Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dL treated with statins versus no lipid-lowering drug // Am. J. Cardiol. — 2002. — Vol. 90, № 2. — P. 147-149.

Aronow W.S., Ahn C. Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins // Heart Dis. — 2002. — Vol. 4, № 3. — P. 159-161.

Pedersen T.R., Faergeman O., Kastelein J.J. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial // J. Am. Med. Assoc. — 2005. — Vol. 294, № 19. — P. 2437-2445.

Ravipati G., Aronow W.S., Ahn C. et al. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins // Am. J. Cardiol. — 2006. — Vol. 98, № 9. — P. 1170-1171.

Sukhija R., Aronow W.S., Sandhu R., Kakar P., Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins // Am. J. Cardiol. — 2006. — Vol. 97, № 2. — P. 279-280.

Afilalo J., Duque G., Steele R. et al. Statins for secondary prevention in elderly patients // J. Am. Coll. Cardiol. — 2008. — Vol. 51, № 1. — Р. 37-45.

Sukhija R., Bursac Z., Kakar P. et al. Effect of statins on the development of renal dysfunction // Am. J. Cardiol. — 2008. — Vol. 101, № 7. — P. 975-979.

Foody J.M., Shah R., Galusha D. et al. Statins and mortality among elderly patients hospitalized with heart failure // Circulation. — 2006. — Vol. 113, № 8. — P. 1086-1092.

GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial // Lancet. — 2008. — Vol. 372, № 9645. — P. 1231-1239.

Desai H., Aronow W.S., Ahn C. et al. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter- defibrillator therapy // J. Cardiovasc. Pharmacol. Ther. — 2010. — Vol. 15, № 1. — Р. 37-40.

Zhang Q.L., Koenig W., Raum E. et al. Epidemiology of chronic kidney disease: results from a population of older adults in Germany // Prev. Med. — 2009. — Vol. 48, № 2. — Р. 122-127.

Zolkiewicz M., Sucajtys E., Chmielewski M. et al. Increased rate of cholesterologenesis — a possible cause of hypercholesterolemia in experimental chronic renal failure in rats // Horm. Metab. Res. — 2002. — Vol. 34, № 5. — P. 234-237.

Baigent C., Landry M. Study of heart and renal protection (SHARP) // Kidney Int. — 2003. — Vol. 63. — P. S207-S210.

Baigent C., Landray M.J., Reith C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial // Lancet. — 2011. DOI: 10.1016/SO140- 6736(11)60739-3.

Jick H., Zomberg G.L., Jick S.S. et al. Statins and the risk of dementia // Lancet. — 2000. — Vol. 356, № 9242. — P. 1627-1631.

Rockwood K., Kirkland S., Hogan D.B. et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people // Arch. Neurol. — 2002. — Vol. 59, № 2. — P. 223-227.

King D.S., Jones D.W., Wofford M.R. et al. Cognitive impairment associated with atorvastatin // Presented at the American Allege of Clinical Pharmacy Spring Practice and Research Forum. — Salt Lake City, 2001, April 22-25.

King D.S., Wilburn A.J., Wofford M.R. et al. Cognitive impairment associated with atorvastatin and simvastatin // Pharmacotherapy. — 2003. — Vol. 23, № 12. — Р. 1663-1667.

Orsi A., Sherman O., Woldeselassie Z. Simvastatin-associated memory loss // Pharmacotherapy. — 2001. — Vol. 21, № 6. — Р. 767769.

Wagstaff L.R., Mitton M.W., Arvik B.M., Doraiswamy P.M. Statin-associated memory loss: analysis of 60 case reports and review of the literature // Pharmacotherapy. — 2003. — Vol. 23, № 7. — Р. 871-880. лЕкция Том 17, № 5 / 2011

Trompet S., van Vliet P., de Craen A.J. et al. Pravastatin and cognitive function in the elderly: results of the PROSPER study // J. Neurol. — Vol. 257, № 1. — Р. 85-90.

Dale K.M., Coleman C.I., Henyan N.N. et al. Statins and cancer risk: a meta-analysis // J. Am. Med. Assoc. — 2006. — Vol. 295, № 1. — Р. 74-80.

Gransbo K., Melander O., Wallentin L. et al. Cardiovascular and cancer mortality in very elderly post-infarction patients receiving statin treatment // J. Am. Coll. Cardiol. — 2010. — Vol. 55. № 13. — P. 1362-1369.

Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment: Panel III) // J. Am. Med. Assoc. — 2001. — Vol. 285, № 19. — P. 2486-2497.

Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines // Circulation. — 2004. — Vol. 1, № 10. — Р. 227-239.

Warshafsky S., Packard D., Marks S.J. et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke // J. Gen. Intern. Med. — 1999. — Vol. 14, № 12. — P. 763-774.

Vergouwen M.D., de Haan R.J., Vermeulen M., Roos Y.B. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovas-cular disease // Stroke. — 2008. — Vol. 39, № 2. — P. 497-502.

The authors declare that there are no conflicts of interest present.